Forum Archive Index - May 2002

["Nick Kearney" <nickk@quicksilver.net.nz>]

SNOOPY

I think you have your wires crossed!

PTD is not in the artificial heart business!

It has steady income from royalties relating to drugs used for Arthritis
(&others).

Cheers

Nk

----- Original Message -----
From: <tennyson@caverock.net.nz>
To: <sharechat@sharechat.co.nz>
Sent: Sunday, May 12, 2002 6:58 AM
Subject: Re: [sharechat] PTD, Gerry and TA.


> Hi Phaedrus,
>
> >
> >
> >Gerry's recommendations have proved to be very reliable and
> >profitable. Nevertheless, the supplementary use of technical
> >analysis to assist in timing entries and exits can enhance these
> >profits. PTD is an excellent example of this.
> >
> >Anyone buying PTD on Gerry's recommendation ($2.30, 29/9/01) would
> >have doubled their money in just over 4 months, only to give all
> >their gains back to the market over the next 3 months. The use of
> >some fairly elementary TA would would have obviated this.
> >
> >
>
>
> Biotech in general, and PTD as a particular example, is IMHO some of
> the toughest territory you can wade into as an investor.   You're
> whole effort may come to nought or you may make your fortune.  And is
> is very hard to pick which technologies will lead to the latter
> path.
>
> Even if a product is technically brilliant there are all sorts of
> clinical multi-stage trial hoops to jump through.   Then, even after
> a trial is over it is not often easy to say whether the trial was a
> 'failure or a success.  Remember the Genesis research psoriasis
> trial last year?   Genesis management gave the result the thumbs up.
> US investors gave the same result the thumbs down!  And the scary
> thing is that depending on how you see the trial will affect the
> business, both opinions can be right!
>
> Often the income of these companies can be from the licensing of a
> patent to another biotech company for further research off on
> another tangent.  This is not always easy to predict.   And generally
> Biotech companies are cash consumers not cash producers.
>
> So where does this leave the biotech investor?   He/She is tossed and
> turned between the vicissitudes of sentiment, riding the highs and
> lows on the way to the pot of gold, or annihilation!  It is amazing
> what you can imagine such a company is worth.  Assuming that a
> company will conquer a global emerging market and I am sure I could
> draw up a convincing business case to show you that PTD is worth $50.
> By the same token I could just as easily draw up a case to show that
> because PTD doesn't have the financial muscle to bring the new
> artificial heart to market, and it is the yet to be introduced
> marketing partner that will be putting up most of the capital and
> taking the risk, that PTD is only worth a few cents.
>
> In the end there are so many factors to consider, so many possible
> scenarios, you can only follow the sentiment of the market, and
> don't invest more money in such a company than you can afford to
> lose.   PTD is the sort of company you must follow closely and the
> ideal tool to do all this is trend analysis.   Personally I'm not in
> the market to invest in such a company as PTD.   But if I was, I'd
> definitely take a course in elementary T/A.   So, surprise surprise
> Phaedrus, I agree with you 100%.
>
> SNOOPY
>
>
>
> ---------------------------------
> Message sent by Snoopy
> e-mail  tennyson@caverock.net.nz
> on Pegasus Mail version 2.55
> ----------------------------------
> "Dogs have big tongues, so you can bet they don't
> bite them by accident"
>
> --------------------------------------------------------------------------
--
> To remove yourself from this list, please use the form at
> http://www.sharechat.co.nz/chat/forum/
>
>


----------------------------------------------------------------------------
To remove yourself from this list, please use the form at
http://www.sharechat.co.nz/chat/forum/